TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38622456
Drug: Pegsitacianine, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegsitacianine, administered intravenously at 1 mg/kg 24-72 hours before surgery
Study: 38622543
Drug: Home Vision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home Vision Therapy Group (new near glasses with accommodative and convergence eye exercises)
Study: 38622608
Drug: Weekly monitoring
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly monitoring by clinical teams
Study: 38622671
Drug: Doppler-guided intraoperative
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doppler-guided intraoperative fluid replacement therapy with lactated Ringer's solution (n = 31)
Study: 38622879
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin 1.8 mg/kg once every 3 weeks with R-CHP for six cycles
Study: 38623494
Drug: Home-based titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based titration of levodopa duodenal infusions (LCIG)
Study: 38625721
Drug: Previous tablet
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous tablet use
Study: 38625800
Drug: Mavacamten (CAMZYOS),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavacamten (CAMZYOS), dosage and duration not available
Study: 38626363
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (target range 80-130 mg/dL)
Study: 38626363
Drug: Standard sliding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sliding scale (80-179 mg/dL)
Study: 38626363
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (intensive insulin vs standard sliding scale)
Study: 38626958
Drug: 4CMenB (Bexsero)
Normalized name: Bexsero
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB (Bexsero) vaccine
Study: 38626982
Drug: Paired serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paired serum samples for RSV antibodies
Study: 38627035
Drug: Selinexor administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor administered at 60 mg weekly as maintenance therapy
Study: 38627114
Drug: Progressive muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive muscle relaxation exercise (15 min daily for 4 weeks)
Study: 38627137
Drug: Preoperative beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative beta-blockers
Study: 38627238
Drug: Derazantinib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Derazantinib monotherapy (300 mg QD in Substudy 1, 200 mg BID in Substudy 5)
Study: 38627238
Drug: Derazantinib 300
Normalized name: Derazantinib
DrugBank: Derazantinib (DB14889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Derazantinib 300 mg QD plus atezolizumab 1200 mg every 3 weeks (Substudy 2)
Study: 38627238
Drug: Derazantinib 200
Normalized name: Derazantinib
DrugBank: Derazantinib (DB14889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Derazantinib 200 mg BID plus atezolizumab 1200 mg every 3 weeks (Substudy 3)
Study: 38627238
Drug: Derazantinib 300
Normalized name: Derazantinib
DrugBank: Derazantinib (DB14889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Derazantinib 300 mg QD monotherapy (Substudy 4)
Study: 38627238
Drug: Derazantinib 300
Normalized name: Derazantinib
DrugBank: Derazantinib (DB14889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Derazantinib 300 mg QD plus atezolizumab 1200 mg every 3 weeks (Substudy 4)
Study: 38627266
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (BLT) - 10,000 lx; daily 30-min sessions for 10 weeks
Study: 38627366
Drug: TQ-B3525, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ-B3525, 20 mg orally once daily in a 28-day cycle
Study: 38627631
Drug: Placebo (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (calcium tablet)
Study: 38627712
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (commercial electrochemical surface treatment)
Study: 38627819
Drug: 3D-printed implant-retained
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D-printed implant-retained mandibular overdentures (IMO)
Study: 38627837
Drug: 30 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 sessions of individual schema therapy
Study: 38627837
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (mainly group-based, short-term cognitive behaviour or psychodynamic therapy)
Study: 38628555
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (varenicline treatment)
Study: 38629062
Drug: COVID-19 Ad5-nCoV
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 Ad5-nCoV adenovirus vaccine
Study: 38629403
Drug: Narrative Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative Therapy
Study: 38629811
Drug: Ketamine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (initial bolus 0.23 mg/kg, continuous infusion 0.58 mg/kg/hr)
Study: 38630186
Drug: Secondary furlow
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary furlow palatoplasty with buccal myomucosal flap (FPBF)
Study: 38630457
Drug: Erenumab 140
Normalized name: Erenumab 140 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab 140 mg subcutaneously every 4 weeks for 12 weeks
Study: 38630471
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics monotherapy (moxifloxacin, 400 mg/d for 7 days)
Study: 38630471
Drug: Combined IV
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined IV and oral antibiotics (IV ertapenem 1 g/d for 2 days plus oral levofloxacin 500 mg/d and metronidazole 500 mg 3 times/d for 5 days)
Study: 38630524
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine alone
Study: 38630524
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) and mindfulness meditation (MM) training
Study: 38630524
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intravenous ketamine and CBT/MM
Study: 38630525
Drug: Humidified high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humidified high-flow nasal oxygen, closed-mouth breathing, at 50 l min -1
Study: 38630525
Drug: Standard nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nasal cannula, closed-mouth breathing, at 50 l min -1
Study: 38630781
Drug: FAP-IL2v (fibroblast
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAP-IL2v (fibroblast activation protein α-targeted IL2 variant) administered intravenously once weekly, starting dose 5 mg, with dose escalation up to 25 mg and various uptitration regimens.
Study: 38630908
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin (2.5 mg/kg) plus pembrolizumab (200 mg)
Study: 38630948
Drug: High-efficacy disease-modifying
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-efficacy disease-modifying treatments (H-DMT, n = 13)
Study: 38630948
Drug: Lower-efficacy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-efficacy treatment
Study: 38630948
Drug: High-efficacy disease-modifying
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-efficacy disease-modifying treatments (H-DMT)
Study: 38631003
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg every 3 weeks for up to 17 cycles)
Study: 38631679
Drug: Standard-of-care oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care oral hygiene regimen
Study: 38631712
Drug: CNCT19 (anti-CD19
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNCT19 (anti-CD19 CAR T-cell) after myeloablative high-dose chemotherapy and autologous stem cell transplantation (HDT/ASCT)
Study: 38631764
Drug: Losmapimod (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod (15 mg twice a day)
Study: 38631826
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg with metformin 1.5 g daily
Study: 38631835
Drug: Stimulant and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant and Placebo
Study: 38632117
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (antibiotics alone or in combination with percutaneous drainage)
Study: 38632262
Drug: Subcutaneous teduglutide
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous teduglutide (n = 26)
Study: 38632457
Drug: SPH3127 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPH3127 50 mg
Study: 38632457
Drug: SPH3127 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPH3127 100 mg
Study: 38632457
Drug: SPH3127 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPH3127 200 mg
Study: 38632501
Drug: EGCG nebulization
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG nebulization 10 ml three times daily for at least seven days, with dose escalation from 1760 umol/L to 8817 umol/L.
Study: 38632501
Drug: EGCG nebulization
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG nebulization at 8817 umol/L.
Study: 38632501
Drug: EGCG nebulization
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG nebulization treatment.
Study: 38632647
Drug: Active theta-burst
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active theta-burst stimulation (TBS) to the left dorsolateral prefrontal cortex (DLPFC) and the vermis of the cerebellum, 1800 stimuli daily for 4 weeks.
Study: 38632661
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: Treatment by ambulance crew and HEMS without prehospital ECPR capabilities
Study: 38632826
Drug: Tezepelumab 210
Normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab 210 mg subcutaneously every 4 weeks (Q4W)
Study: 38632826
Drug: Tezepelumab 210
Normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab 210 mg subcutaneously Q4W
Study: 38633575
Drug: Frontline systemic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frontline systemic therapy at diagnosis or after observation
Study: 38635115
Drug: Medication review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication review with follow-up (intervention group)
Study: 38635245
Drug: Daily motion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily motion discrimination training in the intact field
Study: 38635245
Drug: Daily motion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily motion discrimination training in the blind field
Study: 38635272
Drug: Arthroscopic surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic surgery plus nonoperative management (physical therapy plus medications)
Study: 38635544
Drug: Mindfulness-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based physical exercise (MBPE) program, twice a week over 12 weeks
Study: 38635932
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg orally once daily for 1 year
Study: 38635932
Drug: Enzalutamide treatment
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide treatment
Study: 38635934
Drug: Gemcitabine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine with ATR inhibitor berzosertib
Study: 38636709
Drug: Genomic adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genomic adjusted radiation dose (GARD)
Study: 38636709
Drug: Concurrent chemo-radiotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemo-radiotherapy plus (neo) adjuvant chemotherapy
Study: 38636725
Drug: DTG plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG plus two nucleoside reverse transcriptase inhibitors (NRTIs)
Study: 38636818
Drug: Artificial Intelligence
Normalized name: Intelence
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artificial Intelligence (AI) assessment using the e-Boston Bowel Preparation Scale (e-BBPS)
Study: 38637495
Drug: sintilimab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: sintilimab (200 mg per 3 weeks)
Study: 38637498
Drug: Virus-specific T
Normalized name: Allogeneic JC polyomavirus-specific T-cell therapy
DrugBank: CE-VST01-JC (DB17190)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virus-specific T cell (VST) therapy targeting cytomegalovirus, Epstein-Barr virus, or adenovirus
Study: 38637498
Drug: Corticosteroids, graft-versus-host
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids, graft-versus-host disease, transplant-associated thrombotic microangiopathy, and eculizumab treatment
Study: 38637755
Drug: Adjunctive registered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive registered nurse-based care (Quality Liver Nursing Care Model - QLiNCaM)
Study: 38637772
Drug: External radiotherapy
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External radiotherapy (≥45 Gy, 2-2.5 Gy per fraction) followed by anti-PD-1 immunotherapy (camrelizumab 200 mg once every 3 weeks)
Study: 38637829
Drug: Angiotensin-II treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-II treatment in ACEi/ARB-unexposed patients
Study: 38637829
Drug: Angiotensin-II treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-II treatment in ACEi-exposed patients
Study: 38637829
Drug: Angiotensin-II treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-II treatment in ARB-exposed patients
Study: 38638180
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) and medical management
Study: 38638399
Drug: Prophylactic metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic metformin plus endocrine therapy (ET)
Study: 38638673
Drug: Zilucoplan 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilucoplan 0.3 mg/kg, self-administered subcutaneously, daily
Study: 38638673
Drug: Zilucoplan 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilucoplan 0.3 mg/kg
Study: 38638867
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg (n = 10)
Study: 38638867
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg (n = 12)
Study: 38639433
Drug: Lurasidone (20-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (20-120 mg/d) with lithium
Study: 38639433
Drug: Lurasidone (20-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (20-120 mg/d) with valproate
Study: 38639433
Drug: Lurasidone (20-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (20-120 mg/d) with lithium or valproate
Study: 38639940
Drug: Self-administered acupressure
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered acupressure (SAA) with brief knee health education (KHE); practiced twice daily for 12 weeks.
Study: 38640068
Drug: OnabotulinumtoxinA low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: OnabotulinumtoxinA low dose (LD)
Study: 38640068
Drug: OnabotulinumtoxinA high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: OnabotulinumtoxinA high dose (HD)
Study: 38640200
Drug: Etavopivat 400
Normalized name: Etavopivat
DrugBank: Etavopivat (DB18176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etavopivat 400 mg once daily for 12 weeks (Open-label cohort)
Study: 38640327
Drug: Turkish version
Normalized name: Turkish Licorice Root
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turkish version of the QoR-15 questionnaire (QoR-15T) administered preoperatively and 24 hours postoperatively
Study: 38640500
Drug: Pudendal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudendal nerve block (PNB) with 20 mL of 0.5% bupivacaine
Study: 38640617
Drug: GATT-Patch
Normalized name: Gattex
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: GATT-Patch
Study: 38640748
Drug: PF-06939999 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06939999 0.5 mg q.d. to 6 mg b.i.d. (part 1 dose escalation)
Study: 38640748
Drug: PF-06939999 6
Normalized name: FERMENT COMPLEX 6/PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06939999 6 mg q.d. (part 2 dose expansion)
Study: 38640958
Drug: 3HP (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3HP (weekly isoniazid plus rifapentine for 3 months)
Study: 38640958
Drug: 9H (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9H (daily isoniazid for 9 months)
Study: 38641363
Drug: Stopping proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping proton pump inhibitors (PPIs) for 1 and 2 weeks
Study: 38641363
Drug: Acidic bile
Normalized name: bile salts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidic bile salt solutions (ABS) treatment in Barrett's cells
Study: 38641363
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of BO spheroids after ABS treatment
Study: 38641716
Drug: PROactive daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROactive daily diary
Study: 38641768
Drug: L-PF-35 Dyspnea
Normalized name: L-3,5,3'-Triiodothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-PF-35 Dyspnea domain score
Study: 38641773
Drug: SCRT (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCRT (25 Gy in five fractions over 1 week) plus chemotherapy (4 cycles of CAPOX or 6 cycles of mFOLFOX) and Cadonilimab
Study: 38641773
Drug: SCRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCRT plus chemotherapy and Cadonilimab
Study: 38641998
Drug: Sibeprenlimab (intravenous)
Normalized name: Sibeprenlimab
DrugBank: Sibeprenlimab (DB18919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibeprenlimab (intravenous)
Study: 38642245
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus endocrine therapy (ET) as first-line treatment
Study: 38642245
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus endocrine therapy (ET) as second-line treatment
Study: 38642937
Drug: ivonescimab 20
Normalized name: Ivonescimab
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivonescimab 20 mg/kg every 2 weeks
Study: 38643311
Drug: Capivasertib 400
Normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capivasertib 400 mg BID (4 days on/3 days off)
Study: 38643311
Drug: Midazolam 1
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 1 mg (alone on day 1, and on days 8 and 12 with capivasertib)
Study: 38643346
Drug: Ruxolitinib (RUX)
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib (RUX) 15 mg twice daily and methylprednisolone (MP) 40 mg every other day
Study: 38643346
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of Lenalidomide (LEN) 10 mg once daily on days 1-21 within a 28-day cycle to RUX and MP
Study: 38643547
Drug: AZD1222 COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1222 COVID-19 vaccine (two doses)
Study: 38643782
Drug: Optimised medical
Normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised medical treatment
Study: 38644146
Drug: Darolutamide 600
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darolutamide 600 mg orally twice daily with ADT + docetaxel
Study: 38644588
Drug: First-line infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: First-line infliximab treatment
Study: 38647654
Drug: AG-920 (Articaine)
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-920 (Articaine) ophthalmic solution
Study: 38648264
Drug: Kaplan-Meier curve
Normalized name: Curae
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Kaplan-Meier curve for therapy escalation
Study: 38648575
Drug: Liposomal irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal irinotecan (70 mg/m2 IV)
Study: 38648580
Drug: Natalizumab treatment
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab treatment continued
Study: 38648580
Drug: Natalizumab treatment
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab treatment stopped
Study: 38648814
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (1 g over 10 min followed by 1 g over 8 h)